Eosinophilic granulomatosis with polyangiitis (EGPA) is one of the rarest forms of vasculitis with primary manifestations of moderate-to-severe asthma and peripheral eosinophilia. While early diagnosis can prevent cumulative organ damage, lack of disease awareness and overlap of symptoms with other common conditions often results in delayed recognition of EGPA. Earlier diagnosis can prevent the cumulative organ damage that results from vascular inflammation and eosinophil-dense tissue deposits associated with EGPA. Identification of EGPA requires a high index of suspicion, and conditions with features of eosinophilia and vasculitis need to be ruled out before a diagnosis of EGPA is confirmed. The diagnosis of EGPA relies primarily on the presence of clinical characteristics, as no highly specific or sensitive validated diagnostic tests for EGPA currently exist.
During this 30-minute CMEO Snack, Drs. Wechsler and Dua will identify best practices and current guidelines for the clinical evaluation and differential diagnosis of EGPA. Using a case presentation to frame the discussion, faculty will explain the differential diagnosis of EGPA as well as how to integrate diagnostic methods and interpret results.
Upon completion of this activity, learners will be better able to identify best practices and current guidelines for the clinical evaluation and differential diagnosis of EGPA.
This educational activity is supported by an educational grant from GSK.
Physicians, physician associates (PAs), nurse practitioners (NPs), nurses, and pharmacists specializing in rheumatology, allergy/immunology, pulmonology, nephrologist, internal medicine, and primary care medicine
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Wechsler reports the following financial relationships:
Advisory Board/Consultant: Amgen Inc.; AstraZeneca; Avalo Therapeutics, Inc.; Boehringer Ingelheim; Cerecor Inc.; Cohero Health, Inc.; CytoReason LTD; Eli Lilly and Company; Equillium Bio; GSK; Incyte; Kinaset Therapeutics; Novartis Pharmaceuticals Corporation; Om Pharma; Phylaxis Bioscience, LLC; PULMATRiX, Inc.; RAPT Therapeutics; Regeneron Pharmaceuticals Inc.; Restorbio; Roche/Genentech, Inc.; Sanofi/Genzyme.; Sentien Biotechnologies, Inc.; Sound Biologics; Tetherex Pharmaceuticals; Teva Pharmaceuticals USA, Inc.; and Upstream Bio
Research Support: Amgen Inc.; AstraZeneca; Avalo Therapeutics, Inc.; GSK; Regeneron Pharmaceuticals Inc.; and Sanofi/Genzyme
Speakers Bureau: AstraZeneca; GSK; Regeneron Pharmaceuticals Inc.; and Sanofi
Dr. Dua reports the following financial relationships:
Advisory Board and Consultant: AbbVie Inc.; ChemoCentryx, Inc. (Amgen); Novartis Pharmaceuticals Corporation; and Sanofi
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Call us at 877.CME.PROS (877.263.7767).